In vivo and ex vivo assessment of the blood brain barrier integrity in different glioblastoma animal models
- 1.1k Downloads
Blood brain barrier (BBB) disruption is used (pre)clinically as a measure for brain tumor malignancy and grading. During treatment it is one of the parameters followed rigorously to assess therapeutic efficacy. In animal models, both invasive and non-invasive methods are used to determine BBB disruption, among them Evans blue injection prior to sacrifice and T1-weighted magnetic resonance imaging (MRI) post contrast injection. In this study, we have assessed the BBB integrity with the methods mentioned above in two experimental high grade glioma models, namely the GL261 mouse glioblastoma model and the Hs683 human oligodendroglioma model. The GL261 model showed clear BBB integrity loss with both, contrast-enhanced (CE) MRI and Evans blue staining. In contrast, the Hs683 model only displayed BBB disruption with CE-MRI, which was not evident on Evans blue staining, indicating a limited BBB disruption. These results clearly indicate the importance of assessing the BBB integrity status using appropriate methods. Especially when using large therapeutic molecules that have difficulties crossing the BBB, care should be taken with the appropriate BBB disruption assessment studies.
KeywordsMagnetic resonance imaging Blood brain barrier Glioma Animal model Contrast agent
We would like to thank Prof. Van Gool and Prof. Kiss for supplying us with GL261 and Hs683 tumor cell lines. Furthermore, we would like to thank Prof. Lambrichts and Ms. Santermans for the use of the equipment of the lab of Histology at Hasselt University. Finally, we would also like to thank Prof Verfaillie for logistic support. We are grateful for the financial support from the European commission for EC-FP7 HEALTH.2011.2.2.1–2 (INMiND), from the Flemish government for FWO G0A7514 N, IWT-SBO MIRIAD (130065) and IWT-BRAINSTIM (060838) and from the University of Leuven for the program financing IMIR (PF 10/017).
Conflict of interest
The authors declare that there are no conflicts of interest.
- 12.Hata, N., et al., 2010, Platelet-derived growth factor BB mediates the tropism of human mesenchymal stem cells for malignant gliomas. Neurosurgery. 66(1): p. 144–156; discussion 156–157Google Scholar
- 15.Branle F et al (2002) Evaluation of the efficiency of chemotherapy in in vivo orthotopic models of human glioma cells with and without 1p19q deletions and in C6 rat orthotopic allografts serving for the evaluation of surgery combined with chemotherapy. Cancer 95(3):641–655PubMedCrossRefGoogle Scholar